UNSPSC 51181623: Elcatonin

This classification denotes an antithyroid agent with the molecular formula C148H244N42O47, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W0CMS474JK, chemically known as1,7-Dicarbacalcitonin, 1-butanoic acid-26-L-aspartic acid-27-L-valine-29-L-alanine- but generally known as Elcatonin, which bears US NIH Compound Identifier 16129700. European Medicines Agency schedules Methylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06479MIG.

Elcatonin is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elcatonin under HS 29371900 and SITC 54154. As of Q4 2014, ELCATONIN remains the US FDA Preferred Term for this commodity. Elcatonin bears US NLM identifiers UMLS ID C0115656 and NCI Concept Code C96281.

UNSPSC 51181623 Elcatonin, a Commodity code, covers pharmaceutical products supplied through state and local cooperative purchasing arrangements, specifically generic multi-source pharmaceuticals and over-the-counter products distributed across participating government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body for this procurement vehicle. Vendors supply products through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and must meet FDA compliance, current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place. Products must be available in the marketplace by May 15, 2026, and possess expiration dates of at least one year from manufacture with a minimum six-month shelf life. Vendors must carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Pricing submission options include flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, with evaluation weighted heavily on price competitiveness (75 percent).

MMCAP's RFP, posted January 20, 2026 with proposals due March 26, 2026, spans Minnesota and Oregon. The contract term is two years for new responders with optional MMCAP extensions, while incumbent responders' amendments align with existing agreement expirations through June 30, 2028. Award structure allows sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs. No specific dollar values or budget ranges are disclosed, though vendors should anticipate a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation for reporting delays, missed onboarding timelines, or improper class-of-trade denials. The RFP does not identify set-aside designations or restrictions limiting responses to particular business classifications or disadvantaged enterprises.